Literature DB >> 23023712

Molecular pathogenesis of mantle cell lymphoma.

Pedro Jares1, Dolors Colomer, Elias Campo.   

Abstract

Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1 and the cell cycle, disruption of DNA damage response pathways, and activation of cell survival mechanisms contribute to oncogenesis. A small number of tumors lack cyclin D1 overexpression, suggesting that its dysregulation is always not required for tumor initiation. Some cases have hypermutated IGHV and stable karyotypes, a predominant nonnodal disease, and an indolent clinical evolution, which suggests that they may correspond to distinct subtypes of the disease. In this review, we discuss the molecular pathways that contribute to pathogenesis, and how improved understanding of these molecular mechanisms offers new perspectives for the treatment of patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023712      PMCID: PMC3461905          DOI: 10.1172/JCI61272

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  109 in total

1.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.

Authors:  Lina Nygren; Stefanie Baumgartner Wennerholm; Monika Klimkowska; Birger Christensson; Eva Kimby; Birgitta Sander
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

Review 2.  The complex landscape of genetic alterations in mantle cell lymphoma.

Authors:  Cristina Royo; Itziar Salaverria; Elena M Hartmann; Andreas Rosenwald; Elías Campo; Sílvia Beà
Journal:  Semin Cancer Biol       Date:  2011-09-18       Impact factor: 15.707

3.  Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

Authors:  Mamta Gupta; Andrea E Wahner Hendrickson; Seong Seok Yun; Jing Jing Han; Paula A Schneider; Brian D Koh; Mary J Stenson; Linda E Wellik; Jennifer C Shing; Kevin L Peterson; Karen S Flatten; Allan D Hess; B Douglas Smith; Judith E Karp; Sharon Barr; Thomas E Witzig; Scott H Kaufmann
Journal:  Blood       Date:  2011-11-11       Impact factor: 22.113

Review 4.  Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-06-22

5.  ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Authors:  Chris T Williamson; Huong Muzik; Ali G Turhan; Alberto Zamò; Mark J O'Connor; D Gwyn Bebb; Susan P Lees-Miller
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

6.  Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  C Tom Kouroukis; Andrew Belch; Michael Crump; Elizabeth Eisenhauer; Randy D Gascoyne; Ralph Meyer; Reinhard Lohmann; Pedro Lopez; Jean Powers; Robert Turner; Joseph M Connors
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

Review 7.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

8.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

9.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Authors:  Alba Navarro; Guillem Clot; Cristina Royo; Pedro Jares; Anastasia Hadzidimitriou; Andreas Agathangelidis; Vasilis Bikos; Nikos Darzentas; Theodora Papadaki; Itziar Salaverria; Magda Pinyol; Xavier Puig; Jara Palomero; Maria Carmela Vegliante; Virgina Amador; Alejandra Martinez-Trillos; Lenka Stefancikova; Adrian Wiestner; Wyndham Wilson; Christiane Pott; Maria Jose Calasanz; Nicola Trim; Wendy Erber; Birgitta Sander; German Ott; Andreas Rosenwald; Dolors Colomer; Eva Giné; Reiner Siebert; Armando Lopez-Guillermo; Kostas Stamatopoulos; Sílvia Beà; Elías Campo
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

Review 10.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.

Authors:  M Vogler; D Dinsdale; M J S Dyer; G M Cohen
Journal:  Cell Death Differ       Date:  2008-09-19       Impact factor: 15.828

View more
  134 in total

1.  Nuclear localization of translocation partners in differentiating B-cells.

Authors:  I V Sklyar; A M Pichugin; S V Razin; E S Vassetzky; O V Iarovaia
Journal:  Dokl Biochem Biophys       Date:  2015-10-31       Impact factor: 0.788

2.  SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6.

Authors:  J Palomero; M C Vegliante; A Eguileor; M L Rodríguez; P Balsas; D Martínez; E Campo; V Amador
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

3.  Mantle cell lymphoma harboring Burkitt's-like translocations presents differential expression of aurora kinase genes compared with others 8q abnormalities.

Authors:  Fábio Morato de Oliveira; Ana Paula Nunes Rodrigues-Alves; Antônio Roberto Lucena-Araújo; Ferdinando de Paula Silva; Fernanda Borges da Silva; Roberto Passetto Falcão
Journal:  Med Oncol       Date:  2014-03-29       Impact factor: 3.064

Review 4.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

5.  Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes.

Authors:  Inbal Hazan-Halevy; Daniel Rosenblum; Shiri Weinstein; Osnat Bairey; Pia Raanani; Dan Peer
Journal:  Cancer Lett       Date:  2015-04-28       Impact factor: 8.679

6.  CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

Authors:  David Martín-Garcia; Alba Navarro; Rafael Valdés-Mas; Guillem Clot; Jesús Gutiérrez-Abril; Miriam Prieto; Inmaculada Ribera-Cortada; Renata Woroniecka; Grzegorz Rymkiewicz; Susanne Bens; Laurence de Leval; Andreas Rosenwald; Judith A Ferry; Eric D Hsi; Kai Fu; Jan Delabie; Dennis Weisenburger; Daphne de Jong; Fina Climent; Sheila J O'Connor; Steven H Swerdlow; David Torrents; Sergi Beltran; Blanca Espinet; Blanca González-Farré; Luis Veloza; Dolors Costa; Estella Matutes; Reiner Siebert; German Ott; Leticia Quintanilla-Martinez; Elaine S Jaffe; Carlos López-Otín; Itziar Salaverria; Xose S Puente; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2018-12-11       Impact factor: 22.113

7.  Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.

Authors:  Richard J Lin; Caleb Ho; Patrick D Hilden; Juliet N Barker; Sergio A Giralt; Paul A Hamlin; Ann A Jakubowski; Hugo R Castro-Malaspina; Kevin S Robinson; Esperanza B Papadopoulos; Miguel-Angel Perales; Craig S Sauter
Journal:  Br J Haematol       Date:  2018-12-11       Impact factor: 6.998

8.  A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Authors:  Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 9.  Therapy-related B lymphoblastic leukemia with t(4;11)(q21;q23)/AF4-MLL in a patient with mantle cell lymphoma after recent aggressive chemotherapy: a unique case report.

Authors:  Stephanie L Holdener; Lacey Harrington; Johnny Nguyen; Pedro Horna; Elizabeth Sagatys; Bijal Shah; Ling Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 10.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.